(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), an immuno-oncology company
developing drug candidates for the prevention and treatment of cancer, provides a strategic update of its LDOS47 clinical program.
13 November 2018